FDA Wins Major 9th Circuit Court Ruling on Stem Cell Regulation

The U.S. Food and Drug Administration (FDA) secured a significant victory in a federal appeals court, which affirmed the agency's authority to regulate stem cell clinics. The 9th Circuit Court of Appeals ruled in favor of the FDA, allowing it to classify adipose cell therapies as drugs. This decision, which was unanimous on four parts, reinforces the FDA's regulatory power over stem cell treatments, a closely watched issue in the medical community.